Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication
The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.
1. An ophthalmic contact lens with an outer surface and an inner surface and a composition comprising proteoglycan 4 (PRG4), wherein said composition is disposed on at least a portion of the outer or inner surfaces at a concentration of PRG4 of at least 10 μg/mL and in an amount effective to reduce tear osmolarity so as to relieve dysfunction of tear film or dry eye disease and symptoms associated therewith in an ocular environment of an individual wearing the ophthalmic contact lens.
2. The lens of claim 1 , wherein the PRG4 is bound to said portion of the outer or inner surface.
3. The lens of claim 2 , wherein the PRG4 binds to said portion of the outer or inner surface following a transient shearing event.
4. The lens of claim 1 , wherein the composition comprises a gel forming agent, a surfactant, or a combination thereof.
5. The lens of claim 1 , wherein the composition comprises at least one gel forming agent, the at least one gel forming agent comprising an effective amount of hyaluronic acid, sodium hyaluronate, or a combination thereof.
6. The lens of claim 4 , wherein the surfactant comprises an effective amount of one or more surface active phospholipids.
7. The lens of claim 6 , wherein the surfactant active phospholipid is selected from the group consisting of L-α-dipalmitoylphosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin.
8. The lens of claim 1 , wherein the PRG4 has an average molar mass of between 50 kDa and 400 kDa, and comprises recombinant PGR4, isolated naturally occurring PGR4, or a functional fragment thereof.
9. The lens of claim 4 , wherein the composition further comprises one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, an ophthalmically acceptable excipient, an ophthalmically acceptable astringent, an ophthalmically acceptable vasoconstrictor, an ophthalmically acceptable emollient, and tear electrolytes.
10. A method for reducing tear osmolarity so as to relieve dysfunction of tear film or dry eye disease and symptoms associated therewith in an individual in need thereof, comprising applying to the surface of an eye of the individual the ophthalmic contact lens of claim 1 .
11. The method of claim 10 , wherein the PRG4 is bound to the ophthalmic contact lens.
12. The method of claim 11 , wherein the PRG4 binds to the ophthalmic contact lens following a transient shearing event.
13. The method of claim 10 , wherein the composition further comprises at least one of hyaluronic acid, sodium hyaluronate, one or more surface active phospholipids, or a combination thereof.
14. The method of claim 13 , further comprising replenishing the hyaluronic acid, sodium hyaluronate, and/or surface active phospholipid(s) by applying a topical artificial tear drop or rewetting solution.
15. The method of claim 13 , further comprising replenishing the hyaluronic acid, sodium hyaluronate, and/or surface active phospholipid(s) by treating the ophthalmic lens with a contact lens cleaning product, an overnight incubation, and/or other contact lens care products.
16. The lens of claim 1 , wherein the concentration of PRG4 is 10-500 μg/mL.
17. The lens of claim 1 , wherein the concentration of PRG4 is 100-300 μg/mL.
18. The lens of claim 1 , wherein the concentration of PRG4 is 100 μg/mL.
19. The lens of claim 1 , wherein the concentration of PRG4 is 200 μg/mL.
20. The method of claim 10 , wherein the concentration of PRG4 is 10-500 μg/mL.
21. The method of claim 10 , wherein the concentration of PRG4 is 100-300 μg/mL.
22. The method of claim 10 , wherein the concentration of PRG4 is 100 μg/mL.
23. The method of claim 10 , wherein the concentration of PRG4 is 200 μg/mL.